Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium

Todd M. Gibson,Karin E. Smedby,Christine F. Skibola,David W. Hein,Susan L Slager,Silvia de Sanjosé,Claire M. Vajdic,Yawei Zhang,Brian C.-H. Chiu,Sophia S. Wang,Henrik Hjalgrim,Alexandra Nieters,Paige M. Bracci,Anne Kricker,Tongzhang Zheng,Carol Kolar,James R. Cerhan,Hatef Darabi,Nikolaus Becker,Lucia Conde,Theodore R. Holford,Dennis D. Weisenburger,Anneclaire J. De Roos,Katja Butterbach,Jacques Riby,Wendy Cozen,Yolanda Benavente,Casey Palmers,Elizabeth A. Holly,Joshua N. Sampson,Nathaniel Rothman,Bruce K. Armstrong,Lindsay M. Morton

Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium

2013

Purpose Studies of smoking and risk of non-Hodgkin lymphoma (NHL) have yielded inconsistent results, possibly due to subtype heterogeneity and/or genetic variation impacting the metabolism of tobacco-derived carcinogens, including substrates of the N-acetyltransferase enzymes NAT1 and NAT2.

Keywords:

Gynecology
Lymphoma
Follicular lymphoma
Genetic variation
Cancer
Cancer research
Immunology
Medicine
Young adult
Hematology
Internal medicine
Molecular genetics
Case-control study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations